Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of HDM1005 Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial

NCT07279194 is registered in ClinicalTrials.gov with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07279194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07279194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of HDM1005 Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
October 14, 2025
Completion date
December 13, 2026
Enrollment
825 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity & overweight